In Q1 2023, Foresite Capital held 7 positions worth $132.3M. They initiated 6 new positions and exited 2. Their largest holding was PHVS ($26.2M). Portfolio value grew +398.7% versus the prior quarter.
Frequently asked questions
What stocks did Foresite Capital own in Q1 2023?
Foresite Capital held 7 biotech stocks in their 13F portfolio in Q1 2023. Their top positions include PHVS, LYEL, ACRS, KURA, SNDX. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Foresite Capital's portfolio worth in Q1 2023?
Foresite Capital's tracked biotech portfolio was worth $132.3M across 7 positions, with total assets under management of approximately $4B. Portfolio values are based on 13F filings with the SEC.
What did Foresite Capital buy in Q1 2023?
Foresite Capital initiated 6 new positions in Q1 2023, including PHVS, LYEL, ACRS, KURA, SNDX and 1 more. They also increased 1 existing positions.
What did Foresite Capital sell in Q1 2023?
Foresite Capital fully exited 2 positions in Q1 2023, including ASND, NTRA. They also trimmed 0 existing positions.
Is Foresite Capital a biotech fund?
Data science-driven healthcare crossover fund investing from late-stage private through public equity. Uses proprietary data analytics and clinical expertise to identify asymmetric risk/reward opportunities across biotech and life sciences.
Want AI analysis, insider signals, and catalyst overlays for Foresite Capital?
View latest Foresite Capitalportfolio →